Clinical guidelines ‘Hyperprolactinemia’ (draft)

Hyperprolactinemia is a persistent excess of the blood serum prolactin. The syndrome contains various symptoms, the most characteristic is a violation of the reproductive system. There are multiple endogenous and exogenous causes of hyperprolactinemia. The main treatment method is dopamine agonist therapy, in case of prolactinoma existence, surgical and radiation methods can be applied. About 15% of patients are resistant to dopamine agonist therapy, which determines creation of individual management tactics. The article presents a draft of clinical guidelines for the diagnosis and treatment of hyperprolactinemia, which provides a modern examination algorithm, discusses the basic principles of diagnostics and treatment approaches.

1. Wang AT, Mullan RJ, Lane MA, et al. Treatment of hyperprolactinemia: A systematic review and meta-analysis. Syst Rev. 2006;1(1):1-12. doi: https://doi.org/10.1186/2046-4053-1-33

2. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi: https://doi.org/10.1210/jc.2010-1692

3. Donadio F, Barbieri A, Angioni R, et al. Patients with macroprolactinaemia: Clinical and radiological features. Eur J Clin Invest. 2007;37(7):552-557. doi: https://doi.org/10.1111/j.1365-2362.2007.01823.x

4. Joseph McKenna T. Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol (Oxf ). 2009;71(4):466-469. doi: https://doi.org/10.1111/j.1365-2265.2009.03577.x

5. Schlechte J, Dolan K, Sherman B, et al. The natural history of untreated hyperprolactinemia: A prospective analysis. Obstet Gynecol Surv. 1989;44(9):684-685. doi: https://doi.org/10.1097/00006254-198909000-00016

6. Buchfelder M, Schlaffer SM, Zhao Y. The optimal surgical techniques for pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101299. doi: https://doi.org/10.1016/j.beem.2019.101299

7. Jones PS, Swearingen B. Intraoperative MRI for pituitary adenomas. Neurosurg Clin N Am. 2019;30(4):413-420. doi: https://doi.org/10.1016/j.nec.2019.05.003

8. Bayrak A, Saadat P, Mor E, et al. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril. 2005;84(1):181-185. doi: https://doi.org/10.1016/j.fertnstert.2005.01.102

9. Kinoshita M, Tanaka H, Arita H, et al. Pituitary-targeted dynamic contrast-enhanced multisection CT for detecting MR imaging–occult functional pituitary microadenoma. Am J Neuroradiol. 2015;36(5):904-908. doi: https://doi.org/10.3174/ajnr.A4220

10. Tosaka M, Nagaki T, Honda F, et al. Multi-slice computed tomographyassisted endoscopic transsphenoidal surgery for pituitary macroadenoma: A comparison with conventional microscopic transsphenoidal surgery. Neurol Res. 2015;37(11):951-958. doi: https://doi.org/10.1179/1743132815Y.0000000078

11. Buchfelder M, Schlaffer S. Imaging of pituitary pathology. American Journal of Neuroradiology. 2014;36:151-166. doi: https://doi.org/10.1016/B978-0-444-59602-4.00011-3

12. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf ). 2006;65(2):265-273. doi: https://doi.org/10.1111/j.1365-2265.2006.02562.x

13. Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab. 2011;25(6):885-896. doi: https://doi.org/10.1016/j.beem.2011.05.011

14. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study. Neurology. 2006;67(7):1225-1229. doi: https://doi.org/10.1212/01.wnl.0000238508.68593.1d

15. Grigg J, Worsley R, Thew C, et al. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl). 2017;234(22):3279-3297. doi: https://doi.org/10.1007/s00213-017-4730-6

16. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996;14(4):228-238. doi: https://doi.org/10.2165/00002018-199614040-00003

17. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab. 1999;84(7):2518-2522. doi: https://doi.org/10.1210/jcem.84.7.5810

18. Wakil A, Rigby AS, Clark AL, et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008;159(4):11-14. doi: https://doi.org/10.1530/EJE-08-0365

19. Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12(3):153-157. doi: https://doi.org/10.1007/s11102-008-0134-2

20. Herring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf). 2009;70(1):104-108. doi: https://doi.org/10.1111/j.1365-2265.2008.03458.x

21. Devin JK, Lakhani VT, Byrd BF, Blevins LS. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract. 2008;14(6):672-677. doi: https://doi.org/10.4158/EP.14.6.672

22. Lafeber M, Stades AME, Valk GD, et al. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol. 2010;162(4):667-675. doi: https://doi.org/10.1530/EJE-09-0989

23. Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf). 2010;73(3):369-374. doi: https://doi.org/10.1111/j.1365-2265.2010.03827.x

24. Drake WM, Stiles CE, Howlett TA, et al. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab. 2014;99(1):90-96. doi: https://doi.org/10.1210/jc.2013-2254

25. Auriemma RS, Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013;169(3):359-366. doi: https://doi.org/10.1530/EJE-13-0231

26. Salvatori R. Dopamine agonist withdrawal in hyperprolactinemia: when and how. Endocrine. 2018;59(1):4-6. doi: https://doi.org/10.1007/s12020-017-1469-0

27. Xia MY, Lou XH, Lin SJ, Wu ZB. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018;59(1):50-61. doi: https://doi.org/10.1007/s12020-017-1444-9

28. Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349(21):2023-2033. doi: https://doi.org/10.1056/NEJMoa022657

29. Biswas M, Smith J, Jadon D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf). 2005;63(1):26-31. doi: https://doi.org/10.1111/j.1365-2265.2005.02293.x

30. Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: Systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(1):43-51. doi: https://doi.org/10.1210/jc.2009-1238

31. Passos VQ, Souza JJS, Musolino NRC, Bronstein MD. Long-term follow-up of prolactinomas: Normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab. 2002;87(8):3578-3582. doi: https://doi.org/10.1210/jcem.87.8.8722

32. Kwancharoen R, Auriemma RS, Yenokyan G, et al. Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary. 2014;17(5):451-456. doi: https://doi.org/10.1007/s11102-013-0525-x

33. Vilar L, Albuquerque JL, Gadelha PS, et al. Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: Is it worthwhile? Front Endocrinol (Lausanne). 2015;6(5):151-166. doi: https://doi.org/10.3389/fendo.2015.00011

34. Carroll RW, Christodoulou P, Baynes KCR, Kahn DA. Hyperprolactinemia in a patient with a pituitary adenoma receiving antipsychotic drug therapy. J Psychiatr Pract. 2012;18(2):126-129. doi: https://doi.org/10.1097/01.pra.0000413279.95843.b5

35. Dogansen SC, Cikrikcili U, Oruk G, et al. Dopamine agonistinduced impulse control disorders in patients with prolactinoma: A cross-sectional multicenter study. J Clin Endocrinol Metab. 2019;104(7):2527-2534. doi: https://doi.org/10.1210/jc.2018-02202

36. Barake M, Evins AE, Stoeckel L, et al. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: A pilot study. Pituitary. 2014;17(2):150-156. doi: https://doi.org/10.1007/s11102-013-0480-6

37. Bushe C, Yeomans D, Floyd T, Smith SM. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol. 2008;22(S2):56-62. doi: https://doi.org/10.1177/0269881107088436

38. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22(9):1085-1096. doi: https://doi.org/10.1016/S0149-2918(00)80086-7

39. Molitch ME. Drugs and prolactin. Pituitary. 2008;11(2):209-218. doi: https://doi.org/10.1007/s11102-008-0106-6

40. Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: A clinical review. Psychosomatics. 2014;55(1):29-36. doi: https://doi.org/10.1016/j.psym.2013.08.008

41. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995-2010. doi: https://doi.org/10.1210/jc.2005-2847

42. Miyagawa Y, Tsujimura A, Matsumiya K, et al. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: A 30-year retrospective study. J Urol. 2005;173(6):2072-2075. doi: https://doi.org/10.1097/01.ju.0000158133.09197.f4

43. Williams MH. Drugs five years later. Ann Intern Med. 1981;95(4):464. doi: https://doi.org/10.7326/0003-4819-95-4-464

44. Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil Steril. 1987;48(1):67-71. doi: https://doi.org/10.1016/S0015-0282(16)59292-9

45. Aden U, Jung-Hoffmann C, Kuhl H. A randomized crossover study on various hormonal parameters of two triphasic oral contraceptives. Contraception. 1998;58(2):75-81. doi: https://doi.org/10.1016/S0010-7824(98)00071-7

46. Christin-Maître S, Delemer B, Touraine P, Young J. Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris). 2007;68(2-3):106-112. doi: https://doi.org/10.1016/j.ando.2007.03.008

47. Alvarez-Tutor E, Forga-Llenas L, Rodriguez-Erdozain R, et al. Persistent increase of PRL after oral contraceptive treatment. Alterations in dopaminergic regulation as possible etiology. Arch Gynecol Obstet. 1999;263(1-2):45-50. doi: https://doi.org/10.1007/s004040050261

48. Testa G, Vegetti W, Motta T, et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception. 1998;58(2):69-73. doi: https://doi.org/10.1016/S0010-7824(98)00069-9

49. Fraietta R, Zylberstejn DS, Esteves SC. Hypogonadotropic hypogonadism revisited. Clinics. 2013;68(S1):81-88. doi: https://doi.org/10.6061/clinics/2013(Sup01)09

50. Auriemma RS, Galdiero M, Vitale P, et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology. 2015;101(1):66-81. doi: https://doi.org/10.1159/000371851

51. Molitch ME. Management of medically refractory prolactinoma. J Neurooncol. 2014;117(3):421-428. doi: https://doi.org/10.1007/s11060-013-1270-8

52. Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003;6(1):19-27. doi: https://doi.org/10.1023/A:1026225625897

53. Salti IS, Mufarrij IS, Opitz JM. Familial cushing disease. Am J Med Genet. 1981;8(1):91-94. doi: https://doi.org/10.1002/ajmg.1320080111

54. Maiter D. Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology. 2019;109(1):42-50. doi: https://doi.org/10.1159/000495775

55. Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82(3):876-883. doi: https://doi.org/10.1210/jcem.82.3.3822

56. Losa M, Mortini P, Barzaghi R, et al. Surgical treatment of prolactinsecreting pituitary adenomas: Early results and long-term outcome. J Clin Endocrinol Metab. 2002;87(7):3180-3186. doi: https://doi.org/10.1210/jcem.87.7.8645

57. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi: https://doi.org/10.1210/jc.2010-1692

58. Qu X, Wang M, Wang G, et al. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: A singlecenter experience with 87 consecutive cases. Eur J Endocrinol. 2011;164(4):499-504. doi: https://doi.org/10.1530/EJE-10-0961

59. Song Y-J, Chen M-T, Lian W, et al. Surgical treatment for male prolactinoma. Medicine (Baltimore). 2017;96(2):e5833. doi: https://doi.org/10.1097/MD.0000000000005833

60. Lim S, Shahinian H, Maya MM, et al. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7(6):518-520. doi: https://doi.org/10.1016/S1470-2045(06)70728-8

61. McCormack AI, McDonald KL, Gill AJ, et al. Low O6- methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf ). 2009;71(2):226-233. doi: https://doi.org/10.1111/j.1365-2265.2008.03487.x

62. Hagen C, Schroeder HD, Hansen S, et al. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol. 2009;161(4):631-637. doi: https://doi.org/10.1530/EJE-09-0389

63. Kovacs K, Horvath E, Syro LV, et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol. 2007;38(1):185-189. doi: https://doi.org/10.1016/j.humpath.2006.07.014

64. Bush ZM, Longtine JA, Cunningham T, et al. Temozolomide treatment for aggressive pituitary tumors: Correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 2010;95(11):280-290. doi: https://doi.org/10.1210/jc.2010-0441

65. Sheehan JP, Pouratian N, Steiner L, et al. Gamma knife surgery for pituitary adenomas: Factors related to radiological and endocrine outcomes: Clinical article. J Neurosurg. 2011;114(2):303-309. doi: https://doi.org/10.3171/2010.5.JNS091635

66. Erridge SC, Conkey DS, Stockton D, et al. Radiotherapy for pituitary adenomas: Long-term efficacy and toxicity. Radiother Oncol. 2009;93(3):597-601. doi: https://doi.org/10.1016/j.radonc.2009.09.011

67. Ronson BB, Schulte RW, Han KP, et al. Fractionated proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys. 2006;64(2):425-434. doi: https://doi.org/10.1016/j.ijrobp.2005.07.978

68. Pouratian N, Sheehan J, Jagannathan J, et al. Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery. 2006;59(2):255-264. doi: https://doi.org/10.1227/01.NEU.0000223445.22938.BD

69. Castinetti F, Nagai M, Morange I, et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab. 2009;94(9):3400-3407. doi: https://doi.org/10.1210/jc.2008-2772

70. Ježková J, Hána V, Kršek M, et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol (Oxf ). 2009;70(5):732-741. doi: https://doi.org/10.1111/j.1365-2265.2008.03384.x

71. Tsang RW, Brierley JD, Panzarella T, et al. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother Oncol. 1996;41(1):45-53. doi: https://doi.org/10.1016/S0167-8140(96)91807-1

72. Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil Steril. 1979;31(4):363-372. doi: https://doi.org/10.1016/s0015-0282(16)43929-4

73. Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Obstet Gynecol Surv. 1995;50(3):199-201. doi: https://doi.org/10.1097/00006254-199503000-00020

74. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27(5):485-534. doi: https://doi.org/10.1210/er.2005-9998

75. Pekić S, Medic Stojanoska M, Popovic V. Hyperprolactinemia/ prolactinomas in the postmenopausal period: Challenges in diagnosis and management. Neuroendocrinology. 2019;109(1):28-33. doi: https://doi.org/10.1159/000494725

76. Santharam S, Fountas A, Tampourlou M, et al. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol (Oxf ). 2018;89(3):346-353. doi: https://doi.org/10.1111/cen.13765

77. Colao A, Abs R, Bárcena DG, et al. Pregnancy outcomes following cabergoline treatment: Extended results from a 12-year observational study. Clin Endocrinol (Oxf ). 2008;68(1):66-71. doi: https://doi.org/10.1111/j.1365-2265.2007.03000.x

78. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol. 1996;10(4):333-337. doi: https://doi.org/10.1016/0890-6238(96)00063-9

79. Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary. 2020;23(1):65-69. doi: https://doi.org/10.1007/s11102-019-01010-5

80. Levin G, Rottenstreich A. Prolactin, prolactin disorders, and dopamine agonists during pregnancy. Hormones. 2019;18(2):137-139. doi: https://doi.org/10.1007/s42000-018-0071-z

81. Bronstein MD. Prolactinomas and pregnancy. Pituitary. 2005;8(1):31-38. doi: https://doi.org/10.1007/s11102-005-5083-4

82. Rigg LA, Lein A, Yen SSC. Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol. 1977;129(4):454-456. doi: https://doi.org/10.1016/0002-9378(77)90594-4

83. Gonzalez JG, Elizondo G, Saldivar D, et al. Pituitary gland growth during normal pregnancy: An in Vivo study using magnetic resonance imaging. Am J Med. 1988;85(2):217-220. doi: https://doi.org/10.1016/S0002-9343(88)80346-2

84. Daly AF, Beckers A. Update on the treatment of pituitary adenomas: Familial and genetic considerations. Acta Clin Belg. 2008;63(6):418-424. doi: https://doi.org/10.1179/acb.2008.086

85. Crosignani PG, Mattei AM, Severini V, et al. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol. 1992;44(3):175-180. doi: https://doi.org/10.1016/0028-2243(92)90094-F

86. Molitch ME. Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am. 2006;35(1):99-116. doi: https://doi.org/10.1016/j.ecl.2005.09.011

87. Konopka P, Raymond JP, Merceron RE, Seneze J. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol. 1983;146(8):935-938. doi: https://doi.org/10.1016/0002-9378(83)90968-7

88. van Roon E, van Der Vijver JCM, Gerretsen G, et al. Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy. Fertil Steril. 1981;36(2):173-177. doi: https://doi.org/10.1016/S0015-0282(16)45674-8

89. Liu C, Tyrrell JB. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary. 2001;4(3):179-185. doi: https://doi.org/10.1023/A:1015319007880

90. Iglesias P, Díez JJ. Macroprolactinoma: a diagnostic and therapeutic update. QJM. 2013;106(6):495-504. doi: https://doi.org/10.1093/qjmed/hcs240

91. Donoho DA, Laws ER. The role of surgery in the management of prolactinomas. Neurosurg Clin N Am. 2019;30(4):509-514. doi: https://doi.org/10.1016/j.nec.2019.05.010

92. Molitch ME. Endocrinology in pregnancy: Management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172(5):R205-R213. doi: https://doi.org/10.1530/EJE-14-0848

93. Huang W, Molitch ME. Pituitary tumors in pregnancy. Endocrinol Metab Clin North Am. 2019;48(3):569-581. doi: https://doi.org/10.1016/j.ecl.2019.05.004

94. Domingue ME, Devuyst F, Alexopoulou O, et al. Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol (Oxf ). 2014;80(5):642-648. doi: https://doi.org/10.1111/cen.12370

95. Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline Treatment of Risperidone-Induced Hyperprolactinemia. J Clin Psychiatry. 2004;65(2):187-190. doi: https://doi.org/10.4088/JCP.v65n0207

96. Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am. 1992;21(4):877-901. doi: https://doi.org/10.1016/S0889-8529(18)30193-2

97. Delcour C, Robin G, Young J, Dewailly D. PCOS and hyperprolactinemia: what do we know in 2019? Clin Med Insights Reprod Heal. 2019;13(4):117955811987192. doi: https://doi.org/10.1177/1179558119871921

98. Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis. 1985;6(4):245-249. doi: https://doi.org/10.1016/S0272-6386(85)80181-5

99. Lim VS, Kathpalia SC, Frohman LA. Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J Clin Endocrinol Metab. 1979;48(1):101-107. doi: https://doi.org/10.1210/jcem-48-1-101

100. Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab. 1980;50(5):846-852. doi: https://doi.org/10.1210/jcem-50-5-846

101. Honbo KS, van Herle AJ, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med. 1978;64(5):782-787. doi: https://doi.org/10.1016/0002-9343(78)90558-2

102. Далантаева Н.С., Дедов И.И. Генетические и обменные особенности семейных изо-лированных аденом гипофиза // Ожирение и метаболизм. — 2013. — Т. 10 — №2. — С. 3-10. [Dalantaeva NS, Dedov II. Genetic and metabolic characteristics of familial isolated pituitary adenomas. Obesity and metabolism. 2013;10(2):3-10. (In Russ.)]. doi: https://doi.org/10.14341/2071-8713-4817

103. Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf ). 2010;72(3):377-382. doi: https://doi.org/10.1111/j.1365-2265.2009.03667.x

104. Benlian P, Giraud S, Lahlou N, et al. Familial acromegaly: a specific clinical entity—Further evidence from the genetic study of a three-generation family. Eur J Endocrinol. 1995;133(4):451-456. doi: https://doi.org/10.1530/eje.0.1330451

105. Trivellin G, Daly AF, Faucz FR, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014;371(25):2363-2374. doi: https://doi.org/10.1056/NEJMoa1408028

106. Xekouki P, Stratakis CA. Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocr Relat Cancer. 2012;19(6):C33-C40. doi: https://doi.org/10.1530/ERC-12-0118

107. Carney JA, Gordon H, Carpenter PC, et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore). 1985;64(4):270-283. doi: https://doi.org/10.1097/00005792-198507000-00007

108. Georgitsi M, De Menis E, Cannavò S, et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol (Oxf ). 2008;69(4):621-627. doi: https://doi.org/10.1111/j.1365-2265.2008.03266.x

109. Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology. 2003;28(S1):69-82. doi: https://doi.org/10.1016/S0306-4530(02)00113-0

110. Knegtering H, van der Moolen AEGM, Castelein S, Kluiter H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28:109-123. doi: https://doi.org/10.1016/S0306-4530(02)00130-0

111. Smith S, Wheeler MJ, Murray R, O’Keane V. The Effects of Antipsychotic-Induced Hyperprolactinaemia on the Hypothalamic-Pituitary-Gonadal Axis. J Clin Psychopharmacol. 2002;22(2):109-114. doi: https://doi.org/10.1097/00004714-200204000-00002

112. Ataya K, Mercado A, Kartaginer J, et al. Bone density and reproductive hormones in patients with neurolepticinduced hyperprolactinemia. Fertil Steril. 1988;50(6):876-881. doi: https://doi.org/10.1016/S0015-0282(16)60365-5

113. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry. 2004;65(12):1607-1618. doi: https://doi.org/10.4088/JCP.v65n1205

114. Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest. 2000;23(11):765-770. doi: https://doi.org/10.1007/BF03345068

115. Serri O, Rasio E, Beauregard H, et al. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. 1983;309(5):280-283. doi: https://doi.org/10.1056/NEJM198308043090505

116. Glezer A, Bronstein MD. Prolactinomas, cabergoline, and pregnancy. Endocrine. 2014;47(1):64-69. doi: https://doi.org/10.1007/s12020-014-0334-7

117. Sant’ Anna BG, Musolino NRC, Gadelha MR, et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary. 2020;23(2):120-128. doi: https://doi.org/10.1007/s11102-019-01008-z